Acephate


Literature identifierStudy typeTest dosageEffective dosageEndocrine-mediated endpointsSystems-level perturbations
PMID:15697179IVR1 mg/kg 1 mg/kgAlterations in immune responsesImmunological endocrine-mediated perturbations
IVR1 mg/kg 1 mg/kgIncreased levels of Corticotropin-releasing hormone (CRH)Neurological endocrine-mediated perturbations
IVR1 mg/kg 1 mg/kgIncrease in corticosterone levelsNeurological endocrine-mediated perturbations
IVR1 mg/kg 1 mg/kgIncreased levels of adrenocortical hormones (ACTH)Metabolic endocrine-mediated perturbations
IVR1 mg/kg 1 mg/kgAffects cytokine signalingImmunological endocrine-mediated perturbations
PMID:33348257IVR23.6 mg/kg 23.6 mg/kgDecreased body weightsMetabolic endocrine-mediated perturbations
IVR23.6 mg/kg 23.6 mg/kgDecreased weights of seminal vesiclesReproductive endocrine-mediated perturbations
IVR23.6 mg/kg 23.6 mg/kgDecreased weights of adrenal glandMetabolic endocrine-mediated perturbations
IVR23.6 mg/kg 23.6 mg/kgOxidative stress in testisReproductive endocrine-mediated perturbations
IVR23.6 mg/kg 23.6 mg/kgChanges in morphology of seminiferous tubulesReproductive endocrine-mediated perturbations
IVR23.6 mg/kg 23.6 mg/kgAlterations in preputial separationReproductive endocrine-mediated perturbations
IVR23.6 mg/kg 23.6 mg/kgDecreased weights of epididymisReproductive endocrine-mediated perturbations
IVR23.6 mg/kg 23.6 mg/kgDecreased vas deferens weightsReproductive endocrine-mediated perturbations
PMID:37717670IVR0.3 - 3 ppm 0.3 - 3 ppmIncreased body weightsMetabolic endocrine-mediated perturbations
IVR0.3 - 3 ppm 0.3 - 3 ppmAffects ovarian follicles populationReproductive endocrine-mediated perturbations
IVR0.3 - 3 ppm 0.3 - 3 ppmChanges in morphology of seminiferous tubulesReproductive endocrine-mediated perturbations
IVR3 ppm 3 ppmDecreased weights of seminal vesiclesReproductive endocrine-mediated perturbations
IVR3 ppm 3 ppmAlterations in vaginal openingReproductive endocrine-mediated perturbations
IVR3 ppm 3 ppmAlterations in preputial separationReproductive endocrine-mediated perturbations
IVR0.3 - 3 ppm 0.3 - 3 ppmAffects anogenital distanceReproductive endocrine-mediated perturbations
PMID:39050668IVR0.3 - 3 ppm 0.3 - 3 ppmChanges in brain morphologyNeurological endocrine-mediated perturbations
IVR0.3 ppm 0.3 ppmInduce behavioral changesNeurological endocrine-mediated perturbations
PMID:3975930IVR100 mg/kg 100 mg/kgDecreased LH levelsReproductive endocrine-mediated perturbations
IVR100 mg/kg 100 mg/kgAffects acetylcholinesterase activityNeurological endocrine-mediated perturbations
IVR50 mg/kg 50 mg/kgDecreased LH levelsReproductive endocrine-mediated perturbations
IVR50 mg/kg 50 mg/kgAffects acetylcholinesterase activityNeurological endocrine-mediated perturbations
IVR400 mg/L 400 mg/LAffects acetylcholinesterase activityNeurological endocrine-mediated perturbations
IVR100 mg/L 100 mg/LAffects acetylcholinesterase activityNeurological endocrine-mediated perturbations
IVR25 mg/L 25 mg/LAffects acetylcholinesterase activityNeurological endocrine-mediated perturbations

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.